Overview

Multi-DOSE Oral Ondansetron for Pediatric Acute GastroEnteritis

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

A phase III, double-blind, parallel-design, randomized, placebo controlled trial to compare multi-dose oral Ondansetron with placebo as treatment for vomiting secondary to acute gastroenteritis (AGE), after Emergency Department discharge.

Phase:

Phase 3

Details

Lead Sponsor:

University of Calgary

Collaborators:

Alberta Children's Hospital Research Institute
Canadian Institutes of Health Research (CIHR)
Children's Hospital Research Institute of Manitoba
The Hospital for Sick Children
Université de Montréal
University of Alberta
University of Manitoba
University of Ottawa
University of Western Ontario, Canada
Women and Children's Health Research Institute (WCHRI)

Treatments:

Ondansetron
Pharmaceutical Solutions